Evolving Insights in the Pathogenesis and Therapy of Cutaneous T-cell lymphoma (Mycosis Fungoides and Sezary Syndrome)

Mycosis Fungoides in the Pediatric Population: Report from an International Childhood Registry of Cutaneous Lymphoma

(2015) Elena Pope et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

(2011) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

Malignant Cutaneous T-Cell Lymphoma Cells Express IL-17 Utilizing the Jak3/Stat3 Signaling Pathway

(2011) Thorbjørn Krejsgaard et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Genetic alterations in Sezary syndrome

(2011) Katarzyna Iżykowska et al.   LEUKEMIA & LYMPHOMA

Bortezomib Induces Nuclear Translocation of I B  Resulting in Gene-Specific Suppression of NF- B-Dependent Transcription and Induction of Apoptosis in CTCL

(2011) A. Juvekar et al.   MOLECULAR CANCER RESEARCH

miRNA expression profiling of mycosis fungoides

(2011) Marloes S. van Kester et al.   Molecular Oncology

MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome

(2011) M G Narducci et al.   Cell Death & Disease

Increased Programmed Death-1 Expression on CD4+ T Cells in Cutaneous T-Cell Lymphoma

(2010) Sara Samimi et al.   ARCHIVES OF DERMATOLOGY

Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia

(2010) K. Balakrishnan et al.   BLOOD

MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential

(2010) E. Ballabio et al.   BLOOD

Novel approach to gene expression profiling in Sézary syndrome

(2010) R.G. Pomerantz et al.   BRITISH JOURNAL OF DERMATOLOGY

Transcriptional Profiles Predict Disease Outcome in Patients with Cutaneous T-Cell Lymphoma

(2010) I. V. Litvinov et al.   CLINICAL CANCER RESEARCH

Histone deacetylase inhibitors in Hodgkin lymphoma

(2010) Daniela Buglio et al.   INVESTIGATIONAL NEW DRUGS

Interleukin-16 as a Marker of Sézary Syndrome Onset and Stage

(2010) Jillian Richmond et al.   JOURNAL OF CLINICAL IMMUNOLOGY

IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease–associated inflammation and lymphomagenesis

(2010) Georgia Malamut et al.   JOURNAL OF CLINICAL INVESTIGATION

Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and Sézary Syndrome: A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

(2010) Rafael F. Duarte et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma

(2010) H. Miles Prince et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal

(2010) Nita Sally Agar et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma

(2010) Kazuhito Yamamoto et al.   JOURNAL OF CLINICAL ONCOLOGY

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

(2010) Sean J. Whittaker et al.   JOURNAL OF CLINICAL ONCOLOGY

Induced Sézary syndrome PBMCs poorly express immune response genes up-regulated in stimulated memory T cells

(2010) Benjamin F. Chong et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Type I interferon: friend or foe?

(2010) Giorgio Trinchieri   JOURNAL OF EXPERIMENTAL MEDICINE

Genome-Wide Analysis of Cutaneous T-Cell Lymphomas Identifies Three Clinically Relevant Classes

(2010) Elodie Laharanne et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma

(2010) Youn H. Kim et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Infectious agents in cutaneous T-cell lymphoma

(2010) Ezra D. Mirvish et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)

(2010) Elise A. Olsen et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Targeting microRNAs in cancer: rationale, strategies and challenges

(2010) Ramiro Garzon et al.   NATURE REVIEWS DRUG DISCOVERY

NF-κB addiction and its role in cancer: ‘one size does not fit all’

(2010) M M Chaturvedi et al.   ONCOGENE

Retinoid X receptor   controls innate inflammatory responses through the up-regulation of chemokine expression

(2010) V. Nunez et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators ofAHI-1oncogene in primary and transformed CTCL cells

(2009) Erin Kennah et al.   BLOOD

Epigenetic regulation of killer immunoglobulin-like receptor expression in T cells

(2009) G. Li et al.   BLOOD

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases

(2009) P. T. Bradford et al.   BLOOD

T-plastin (PLS3) gene expression differentiates Sézary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression

(2009) N. Tang et al.   BRITISH JOURNAL OF DERMATOLOGY

Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients

(2009) J. H. Kunishige et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies

(2009) D. O'Mahony et al.   CLINICAL CANCER RESEARCH

Immunocytochemistry and the diagnosis of cutaneous lymphoma

(2009) Alistair Robson   HISTOPATHOLOGY

Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies

(2009) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

Classification of lymphoid neoplasms: the microscope as a tool for disease discovery

(2008) E. S. Jaffe et al.   BLOOD

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

(2008) G. Garcia-Manero et al.   BLOOD

Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines

(2008) M. A. Morse et al.   BLOOD

Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome

(2008) R. van Doorn et al.   BLOOD

Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma

(2008) R F Duarte et al.   BONE MARROW TRANSPLANTATION

Psoralen plus ultraviolet A ± interferon-α treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-κB and T-cell receptor pathways

(2008) M.B. Wozniak et al.   BRITISH JOURNAL OF DERMATOLOGY

Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse model

(2008) Asahi Ito et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Novel and Highly Recurrent Chromosomal Alterations in Sezary Syndrome

(2008) M. H. Vermeer et al.   CANCER RESEARCH

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

(2008) L. Gore et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

(2008) J. S. de Bono et al.   CLINICAL CANCER RESEARCH

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

(2008) L. Ellis et al.   CLINICAL CANCER RESEARCH

Immune Function Abnormalities in Peripheral Blood Mononuclear Cell Cytokine Expression Differentiates Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides

(2008) B. F. Chong et al.   CLINICAL CANCER RESEARCH

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

(2008) Peter Gimsing et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

A genomic and expression study of AP-1 in primary cutaneous T-cell lymphoma: evidence for dysregulated expression of JUNB and JUND in MF and SS

(2008) Xin Mao et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Mycosis fungoides and Sézary syndrome

(2008) Sam T Hwang et al.   LANCET

Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma

(2008) Elisabetta Capriotti et al.   LEUKEMIA & LYMPHOMA

CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sézary syndrome by flow cytometry

(2007) David W. Bahler et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly

(2007) Lapo Alinari et al.   LEUKEMIA RESEARCH